Repligen (NASDAQ:RGEN) Releases FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.670-1.760 for the period, compared to the consensus EPS estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Repligen Stock Up 6.4 %

Repligen stock traded up $9.72 during mid-day trading on Thursday, hitting $160.45. The company had a trading volume of 836,138 shares, compared to its average volume of 573,573. The company has a market capitalization of $8.99 billion, a PE ratio of -432.67, a price-to-earnings-growth ratio of 4.08 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13. The stock’s 50 day moving average price is $155.04 and its two-hundred day moving average price is $148.71.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. As a group, sell-side analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $182.91.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.